TDO Fluorogenic Inhibitor Screening Assay Kit -384 (Human)

Catalog #
72049
$1,125 *
Size: 384 wells
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The TDO Fluorogenic Inhibitor Screening Assay Kit is designed to measure enzyme inhibition of tryptophan 2,3-dioxygenase (TDO). The TDO Fluorogenic Inhibitor Screening Assay Kit is simple to use and detects fluorescence at long wavelengths, which minimizes potential errors due to compound interference. In the assay, the inhibitor and enzyme are added to a sample containing L-Trp substrate. After a 1 hour incubation at room temperature, the fluorescence solution is added and incubated at 37°C for four hours. Activity is measured by reading sample fluorescence at λ=510 nm following excitation of the reaction product at λ=400 nm.

Synonyms
TDO2, tryptophan 2,3 dioxygenase, activity assay kit
Product Info
Storage and Usage
Citations
Assay Kit Format
Fluorogenic
Supplied As
The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 400 reactions.
Format
Catalog Number Component Amount Storage
71195 TDO His-Tag* 100 μg -80°C (Avoid freeze/thaw cycles!)
73010 TDO Fluorogenic Reaction Solution 3 x 10 ml -80°C
73006 TDO Buffer 3 ml -80°C
  Fluorescence Solution 4 x 1 ml -80°C
79961 Black 384 Wells Assay-Plate 1    
  Plate sealing film 1    

*The concentration of TDO is lot-specific and will be indicated on the tube containing the enzyme.

UniProt #
P48775
Background
L-tryptophan (L-Trp) is an essential amino acid necessary for protein synthesis in mammalian cells and the L-Trp to kynurenine (Kyn) pathway is firmly established as a key regulator of innate and adaptive immunity. Catabolism of L-Trp to Kyn maintains an immunosuppressive microenvironment by starving immune cells of L-Trp and releasing degradation products of L-Trp that have immunosuppressive functions. Tryptophan 2,3 dioxygenase (TDO), a rate limiting enzymes in this pathway, is upregulated in many tumors, providing cancer cells with an avenue for immune evasion.
References

Seegers, N., et al. J. Biomol. Screen. 2014. 19(9):1266-74.